Evaluation of the Implementation of the Pharmacogenetics and Personalized Medicine Program "MedeA" in the Extremadura Health Service.

NCT ID: NCT06607445

Last Updated: 2024-09-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

6445 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-26

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An open longitudinal observational study, non-randomized, which will include the adult population, attended by the SES, in which preference will be given to those patients under treatment with drugs that can produce relevant adverse effects. It is a naturalistic study in which no pharmacological or other type of intervention will be carried out, only the information recommended in the drug data sheet (pharmacogenetic biomarkers, relevant interactions and clinical contraindications) will be provided.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adverse Drug Event

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lusitania

Primary health care

No interventions assigned to this group

Celtici

Oncology

No interventions assigned to this group

Vettonia

Mental health

No interventions assigned to this group

Turdulia

Internal medicine

No interventions assigned to this group

Lácara

Nephrology

No interventions assigned to this group

Tartessos

Neurology

No interventions assigned to this group

Cancho Roano

Emergencies

No interventions assigned to this group

Oretania

Cardiology

No interventions assigned to this group

Carpetania

Rheumatology

No interventions assigned to this group

Baeturia

Transplants

No interventions assigned to this group

Endovélico

Infectious

No interventions assigned to this group

Sirona

Clinical pharmacology

No interventions assigned to this group

Gaudeamus

University of extremadura

No interventions assigned to this group

Sucellus

Urology

No interventions assigned to this group

Mnemosyne

Neurology-Vascular

No interventions assigned to this group

Paidos

Pediatrics

No interventions assigned to this group

Turuñuelo

Pneumology

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

General criteria for all patients:

* Age ≥ 18 years. In case of minors, they may be included, under the following assumptions:
* If the minor is under 12 years of age, participation will require the consent and signature of the informed consent document by both parents (or their guardian).
* If the minor is between 12 and 16 years of age, a proxy informed consent form will be provided and signed by both parents (if both parents are present at the time of the interview) or only one of them (in which case one of the following two conditions must be stated: that the other parent is not present at the time of the interview but does not object to the participation of the minor in the study or that the signatory is the sole legal guardian of the minor).
* Be registered or potentially/have been attended in the Extremadura Health Service.
* Not have language or communication barrier or present disability being totally dependent on another person.

* Refusal by the patient to be part of the cohort initially, or to continue to be part of the cohort during follow-up.
* Manifest difficulty for follow-up.
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Complejo Hospitalario Universitario de Badajoz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Complejo Hospitalario Universitario de Badajoz

Badajoz, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Adrián LLerena, Doctor

Role: primary

+34 924218040

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MedeA21.01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

YouScript IMPACT Registry
NCT02191358 COMPLETED
Anticoagulation Adherence Measurement Strategies
NCT07129395 ACTIVE_NOT_RECRUITING